Clinical Trial

A Study of Mosliciguat in PH-ILD

Study acronym: PHocus
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center clinical study to evaluate the safety and efficacy of inhaled mosliciguat in participants with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-10-08; most recent amendment 2026-02-19.
Status change: Recruiting → Active, Not Recruiting 2026-02-19
Trial Details
NCT Number NCT06635850
Lead Sponsor Pulmovant, Inc.
Conditions Pulmonary Hypertension, Interstitial Lung Disease, Lung Diseases, Vascular Diseases, Cardiovascular Diseases, Fibrosis
Enrollment 135 participants
Start Date 2024-10-29
Primary Completion 2026-12 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-20